Form 8-K · Current report
ResMed| 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000943819
- Accession no.
- 0001193125-26-437783
Summary
ResMed reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% (7% on a core constant currency basis), with GAAP diluted earnings per share of $2.92, up 23%, and non-GAAP diluted EPS of $2.91, up 14%, while reiterating fiscal 2027 guidance of 5–7% core constant currency revenue growth and $12.00–$12.25 non-GAAP diluted EPS. The company declared a quarterly cash dividend of $0.66 per share, said it closed the divestiture of its MatrixCare business, and announced the U.S. launch of the AirTouch F40 fabric CPAP mask.
Key points
- Q1 FY2027 revenue rose 6% year over year to $1.415 billion, or 7% on a core constant currency basis, which excludes the Noctrix acquisition and MatrixCare divestiture.
- Non-GAAP gross margin expanded 50 basis points to 62.5%, and non-GAAP operating margin was 35.8%.
- ResMed returned more than $1.0 billion to shareholders in the quarter through share repurchases and dividends, with operating cash flow of $422 million and free cash flow of $374 million.
- The board declared a $0.66 per share quarterly dividend with a November 12, 2026 record date and December 17, 2026 payment date; Carol Burt was appointed Lead Director effective November 15, 2026 following Director Ron Taylor's planned retirement.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On October 29, 2026, we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter ended September 30, 2026. The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 8.01. Other Events. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.